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Summary In order to determine whether low plasma levels of retinol and its carrier (retinol binding protein)
are related to increased risk of cancer recurrence, these were measured in 103 patients who had had colorectal
cancer surgically removed. According to the modification of the Dukes' classification, 66 had B2 tumours
(with no nodal involvement' and 37 had C tumours (with lymph-node metastases). These patients were part
of the Cross Cancer Institute Adjuvant GI Cohorts who were on the control arms receiving no further
treatment. At the time of blood sample collection, they were believed to be free of neoplastic disease. The
post-operative patients were found to be associated with subnormal circulatory levels of retinol (43.3 pgdl-1
vs 65.3 pgdl-1) and its carrier protein (4.6mgdl-1 vs 5.7mgdl- 1), when compared with apparently healthy
subjects. The latter being more markedly depressed in patients with "C" type tumour (3.8mgdl-1) than that
in those with "B2" type tumour (5.0mgdl-1). These findings appeared to be persistent during the follow-up
study when a second blood sample was collected, one to four months later from 40 patients. Furthermore, the
initial plasma retinol level in conjunction with RBP was found to be even lower in 12 patients (35.1 pgdl-1,
3.7 mgdl-1) who subsequently had cancer recurrence than in those who remained free of apparent cancer
(44.5 gdl -1, 4.6 mgdl -1). The lowest initial values of retinol (19.3pg; 18.8 pgdl-1) and RBP (2.4;
1.6 mgdl-1) recorded in the study were seen in the only two patients who died of the disease at the time of
follow-up.
The evidence to support a link between retinol
deficiency and cancer in man comes primarily from
three sources. These are epidemiological studies of
dietary intake and cancer incidence (Bjelke, 1975;
Hirayama, 1979; Mettlin & Graham, 1979; Graham
et al., 1981); biochemical studies involving com-
parison of plasma retinol levels in cancer cases and
controls (Basu et al., 1976, 1982; Ibrahim et al.,
1977; Atukorala et al., 1979; and biochemical
studies of retinol status in those who are destined
to develop cancer (Wald et al., 1980; Kark et al.,
1981). These studies have consistently implied that
low plasma or dietary intake of retinol may be
associated with increased risk of developing cancer.
However, there is little or no information in the
literature showing a relationship between retinol
status and subsequent cancer recurrence in patients
who had undergone curative surgery. The present
study was undertaken to investigate whether lower
plasma retinol is associated with increased risk of
cancer recurrence in post-operative, apparently
disease-free colorectal cancer patients.
The mobilization and transportation of retinol
from liver storage requires hydrolysis of the retinyl
esters followed by conjugation of the free retinol
with a specific transport protein, retinol-binding
protein (RBP) produced by the liver. The holo-
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protein is then released to the circulation where it
binds to prealbumin as a 1:1 molar complex. The
resulting complex transports retinol to target
organs (Goodman, 1974; Peterson et al., 1974). In
order to determine the metabolically available reti-
nol, the plasma level of RBP was measured in
conjunction with retinol.
Patients and methods
Patients
A 10-year follow-up of 487 cases of colorectal
cancer at the W.W. Cross Cancer Institute
(WWCCI) in Edmonton, Alberta showed an overall
5-year survival of 35% (McCarten & Preston,
1973). An ongoing randomized prospective surgical
adjuvant GI trial involving Dukes' B2 (with full
thickness of the bowel wall but no nodal involve-
ment) and C (with regional lymph-node metastases)
colorectal carcinoma was initiated in 1976 at the
WWCCI. Patients entering into this trial were ran-
domly assigned into one of the three groups includ-
ing control receiving no adjuvant treatment, im-
munotherapy, and chemoimmunotherapy. All
patients considered for the study were entered as
randomized only if informed consent was given.
Patients were ineligible if they had had pre-
operative radiotherapy, chemotherapy or immuno-
therapy within the previous year. The main assess-
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ment of the trial is survival which will be calculated
for each patient allocated from the data of definite
resection.
The present study was an integral part of the
WWCCI trial. A total of 103 patients who were on
the control arm of the surgical adjuvant trial were
assigned to this investigation. All these patients had
previously undergone curative resections of the
histologically proven colonic and rectal adeno-
carcinomas. Sixty-six patients (36 males and 30
females) has a Dukes' B2 tumour, and 37 (18 males
and 19 females) had a Dukes' C tumour. The
distribution of tumour sites in the patients before
surgery is shown in Table I. At the time of diag-
nosis and surgery, the mean age of the entire group
was 62.6 years, with a range between 23 and 80.
Over 98% of the patients were over 40 years of
age. Sixty-five apparently healthy subjects (34 males
and 31 females) who were Red Cross blood donors
formed the basis of the controls of the study. Their
mean age was 46.5 years with a range between 23
and 65. Over 72% of these subjects were over 40
years. Although such subjects were not an ideal
"control" group, their biochemical values provided
normal ranges for comparison with the results from
the patients, since the same methods were employed
in determining the various indices for both the
"control" subjects and the post-operative colorectal
cancer patients.
Table I Distribution of tumour sites in the
cancer patients before surgery
Total No.
Site of Tumour Dukes B2 Dukes C
Cecum 9 4
Ascending colon 11 4
Descending colon 7 2
Transverse colon 3 2
Flexures 6 4
Recto-sigmoid 16 16
Rectum 14 5
Totals 66 37
Methods
Non-fasting blood samples were drawn from all
subjects in EDTA tubes. The samples were wrapped
with foil during transportation from the WWCCI
and the Red Cross Blood Transfusion Clinics to the
laboratory, thus minimizing the loss of vitamin A
which is sentitive to light. The separated plasma
samples were stored at -35°C until analyzed.
Retinol was determined in the plasma by a
modification (Steveninck & DeGoeij, 1973) of the
fluorometric method of Hansen & Warwick (1968).
In this method, fluorescence was measured at an
emission wavelength of 550nm where interference
from carotenoids was virtually zero. To determine
the metabolically available retinol, plasma con-
centrations of RBP were determined by the single
radial immunodiffusion technique (Mancini et al.,
1965) using LC-partigen immunodiffusion plates
(Behring Diagnostics).
All biochemical analyses were performed blind,
i.e. the classification of the patients was not known
during the study. One-way analysis of variance was
used to determine the significant differences be-
tween the means of the different groups for each of
the variables. The student t-test was used to deter-
mine if there was a significant difference between
means of any two groups. A pairwise t-test was
used to identify any significant change between the
first and second samples for patients who had serial
samples.
Results
The plasma concentrations of retinol and RBP in
the control subjects did not appear to be subject to
age and sex variations (23-65 years). Furthermore,
the mean values of the indices obtained in these
subjects were found to be similar to those reported
by others involving control subjects with age groups
matched with the age of the patients (23-80 years)
included in the present study (Willett et al., 1984;
Stich et al., 1984). The results of our control
subjects as a group, irrespective of age and sex,
were therefore compared with that of the post-
operative colorectal cancer patients. Table II shows
the mean differences in plasma retinol and RBP
between control subjects and the post-operative
colorectal cancer patients who appeared to be
disease-free. Both groups (B2 and C) of disease-free
cancer patients were found to be associated with
not only subnormal plasma retinol levels
(P<0.001), but also lower RBP levels (P<0.01)
than the "control" subjects. Statistical difference of
the RBP levels between "controls" and the patients
Table II Plasma retinol and RBP levels in
postoperative colorectal cancer patients
Retinol RBP
Groups (,ugdl'-) (mgdl-
Controls 65.3+3.2 5.7+0.3
Colorectal B2 43.5 + 1.8a 50+0.3b
Colorectal C 43.1 +2.9a 3.8+0.4a
Each value is the mean +s.e.
aSignificantly different from controls, P<0.001.
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with "C" type colorectal cancer appeared to be
more marked (P<0.001) than the difference be-
tween "controls" and the patients with "B2" type
cancer.
No differences between the cancer sites for reti-
nol and RBP were observed as determined by one-
way analysis of variance. Patients were grouped
together by period intervals from the date of sur-
gery to the date of blood sample collection. The
shortest interval (<2 months) was associated with
the lowest average mean of plasma retinol and RBP
levels, while during the period of 6-12 months
following surgery, the average mean values of the
indices were found to be at their maximum levels.
Analysis of variance, however, revealed no overall
significant difference in these parameters between
the various intervals of time. Of the 103 patients,
40 had serial samples taken at two different periods
of time. The time interval between the first and
second samples ranged from less than one month to
4 months with an average time difference of 2-6
months. No significant differences in plasma con-
centrations of retinol and RBP were observed be-
tween the two periods of time. In follow-up studies
to date, of the 103 apparently disease-free
colorectal cancer patients, a total of 12 subjects
(from both B2 and C groups) subsequently had a
recurrence of the disease who showed lower plasma
levels of retinol as well as RBP, then those who
remained disease-free (Table III). However, when
Table III Plasma retinol and RBP in
patients remaining disease-free and in
patients with subsequent recurrence fol-
lowing surgery
Retinol RBP
Groups (Lgdl-1) (mgdl-1)
Disease-free 44.5+1.6 4.6+0.3
(n =91)
Recurrence 35.1+5.2 3.7+0.4
(n = 12)
Significance 0.05 0.05
(P value)
Each value is the mean+s.e.
the subsequent recurrent cases were removed from
the total of 103 patients who were thought to be
free from colorectal cancer following surgery, the
results of the comparison of the plasma retinol and
RBP levels remained the same as those shown in
Table II where the recurrent cases were included.
It was interesting to note that plasma concen-
trations of retinol and RBP were very low in two
recurrent patients who died of the disease during
this study (Table IV).
Discussion
Plasma from healthy blood donors was used merely
to standardize the methodologies for both retinol
and RBP. Since these subjects had no recent sur-
gery, limited conclusions can be drawn from com-
parisons of the post-operative colorectal cancer
patients' values to these normals. However, it is
interesting to note that although the patients were
seemingly free of colorectal cancer, they had sub-
normal levels of plasma retinol when compared
with the apparently healthy subjects (43.3pgdl-1 vs
65.3pgdl-1). This finding is consistent irrespective
of either the stage of the disease or the site of the
tumour at the time ofdiagnosis.
Subnormal levels of plasma retinol have been
reported in cancers of the bronchus (Basu et al.,
1976); lung (Atukorala et al., 1979); oropharynx
(Ibrahim et al., 1977) and GI tract (Abels et al.,
1941). In these studies, blood samples were taken
from patients who still had a tumour. It is, there-
fore, possible that their appetite was depressed due
to the presence of the tumour, or the tumour itself
may have lowered retinol levels due to its increased
requirement. Moreover, the treatment of the disease
by either chemotherapy or radiotherapy may have
resulted in nutritional problems (Dewys & Walters,
1975).
It is noteworthy to point out that the patients in
the present study had already undergone resection
of their carcinoma, and were believed to be free of
neoplastic disease following surgery when the blood
samples were collected. In addition, these patients
Table IV Plasma retinol and RBP concentrations of the two patients who
died during the study
Survival
following
Age Stage of Primary surgery Retinol RBP
(year) Sex diagnosis site (months) (sgdl 1) (mgdl ')
68 male B2 Sigmoid 5 19.32 2.40
colona
78 male C Ascending 8 18.86 1.68
colona
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were not undergoing any kind of therapy, and yet
they were found to have subnormal circulating
levels of retinol. This was true, not only when the
blood samples were collected soon after surgery,
but also in the subsequent samples collected 1-4
months later.
The low plasma retinol in the postoperative
colorectal cancer patients appears to be associated
with subnormal plasma levels of RBP. Since retinol
is transported to the circulation bound to RBP, the
low plasma retinol in the colorectal cancer patients
may be the result of a lower concentration of the
carrier protein.
With the exception of one study (Willett et al.,
1984), most studies have indicated that subnormal
plasma retinol levels exist long before the ap-
pearance of a tumour. Thus, low circulating levels
of the vitamin were observed in subjects who
subsequently developed cancer of epithelial cell
origin (Wald et al., 1980; Kark et al., 1981).
However, in a case-control study, the plasma con-
centrations of RBP were found to be normal in
samples taken 2-7 years before the development of
clinically manifested lung tumours (Haines et al.,
1982). While there have been a number of studies
showing low concentrations of both plasma retinol
and RBP in patients with an established tumour
(Atukorala et al., 1979; Basu et al., 1982).
It is possible that the circulating level of RBP
could be used as a possible tumour marker. Such a
hypothesis is further substantiated by the observ-
ations made in the present study where colorectal
cancer patients with (Dukes' C) or without (Dukes'
B2) regional lymph-node metastases were found to
be associated with subnormal plasma retinol levels,
while RBP levels appeared to be more markedly
affected in patients with regional lymph-node meta-
stases than those without. Furthermore, in follow-
up studies to date, besides displaying significantly
low plasma retinol values, patients who had a
subsequent recurrence of the disease also had lower
initial mean RBP values than those who remained
free of apparent cancer (3.7mgdl-1 vs 4.6mgdl-D).
Interestingly enough, the lowest initial values of
retinol and RBP recorded in the study were seen in
the only two patients who had died of the disease
at the time of follow-up. However, in view of the
fact that there is a considerable overlap in the
distribution of RBP levels in the patients who do
and those who do not have a recurrence of their
tumour, the possible hypothesis that RBP could be
a tumour marker needs to be made more cautiously
at this stage.
Nonetheless, the results of this study appear to
suggest that plasma retinol levels in the post-
operative disease-free colorectal cancer patient are
lower than those in normals, lower plasma RBP
levels may be correlated with more advanced stages
of resected disease, and there may be a correlation
between poor metabolic vitamin A status and sub-
sequent relapse. These observations may have prog-
nostic and predictive significance in colorectal can-
cer. Further work is certainly warranted to es-
tablish whether retinol supplementations raise the
circulatory levels of the vitamin or would this not
occur due to metabolic unavailability of retinol as a
result of reduced RBP levels.
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